多发性骨髓瘤继发第二肿瘤的回顾性研究  

A retrospective study in second primary malignancy of patients with multiple myeloma

作　　者：夏珺[1] 毛静珏[1] 杨蕾[1] 孙鸿丽[1] 王婧[1] 孙超[1] 郭宏锋[1] 周新[1] 

机构地区：[1]南京医科大学附属无锡市人民医院血液科,江苏省无锡市214023

出　　处：《临床合理用药杂志》2016年第23期11-12,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的回顾性分析多发性骨髓瘤(MM)患者继发第二肿瘤的情况,提高对多发性骨髓瘤继发第二肿瘤的认识。方法回顾性分析2007-2014年医院确诊MM患者94例临床资料,评估所有患者继发第二肿瘤的发生率、第二肿瘤的类型、从治疗至发生第二肿瘤的时间及患者临床表现。结果 91例MM患者治疗过程中继发第二肿瘤4例,发生率4.39%,实体肿瘤及血液肿瘤均有发生。4例患者自诊断MM至第二肿瘤发生平均时间为16月。结论多发性骨髓瘤继发第二肿瘤的发病机制及预后尚不明确,需进一步随访研究,以更好地评估风险与利益,使MM患者获得最佳治疗效果。Objective Retrospective analysis of second primary malignancy of patients with multiple myeloma（MM） to improve the understanding of second primary malignancy of MM. Methods Retrospective analysis of patients from the year 2007 -2014 in hospital diagnosed as MM to assess the incidence of all patients with secondary primary malignancy （SPM）, type of SPM, time from the treatment of MM to the diagnosis of SPM. Results The incidence of SPM in 91 patients admitted to our hospital with MM was 4.39%. Solid tumors and hematological malignancies have occurred. The average time from treatment of MM to the diagnosis of SPM was 16 months. Conclusion The pathogenesis and prognosis of multiple myeloma secondary to second tumors are not clear. Further follow-up study is needed to assess the risks and benefits, and to make the best therapeutic effect for MM patients.

关 键 词：多发性骨髓瘤 继发第二肿瘤 药物应用 

分 类 号：R733.3[医药卫生—肿瘤]